These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 31487564

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P, SAFEHEART Investigators.
    J Am Coll Cardiol; 2016 Mar 22; 67(11):1278-85. PubMed ID: 26988947
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.
    JAMA; 2016 Aug 16; 316(7):743-53. PubMed ID: 27533159
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD.
    Curr Diab Rep; 2019 Nov 21; 19(12):146. PubMed ID: 31754844
    [Abstract] [Full Text] [Related]

  • 11. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
    Puri R, Mehta V, Duell PB, Nair D, Mohan JC, Yusuf J, Dalal JJ, Mishra S, Kasliwal RR, Agarwal R, Mukhopadhyay S, Wardhan H, Khanna NN, Pradhan A, Mehrotra R, Kumar A, Puri S, Muruganathan A, Sattur GB, Yadav M, Singh HP, Agarwal RK, Nanda R.
    J Clin Lipidol; 2020 Nov 21; 14(2):e1-e13. PubMed ID: 32089456
    [Abstract] [Full Text] [Related]

  • 12. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN.
    Atherosclerosis; 2018 Oct 21; 277():308-313. PubMed ID: 30270064
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
    Chlebus K, Zdrojewski T, Gruchała M, Gałąska R, Pajkowski M, Kocejko MR, Chmara M, Pencina MJ.
    Am Heart J; 2019 Dec 21; 218():32-45. PubMed ID: 31706143
    [Abstract] [Full Text] [Related]

  • 14. Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Latkovskis G, Saripo V, Gilis D, Nesterovics G, Upena-Roze A, Erglis A.
    Atherosclerosis; 2018 Oct 21; 277():347-354. PubMed ID: 30270070
    [Abstract] [Full Text] [Related]

  • 15. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G, Taylan C, Büscher R, Schmitt CP, Pape L, Oh J, Driemeyer J, Galiano M, König J, Schürfeld C, Spitthöver R, Schaefer JR, Weber LT, Heibges A, Klingel R.
    Pediatr Nephrol; 2018 Jul 21; 33(7):1199-1208. PubMed ID: 29502162
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators.
    J Clin Lipidol; 2018 Jul 21; 12(4):958-965. PubMed ID: 29685591
    [Abstract] [Full Text] [Related]

  • 17. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S, Akioyamen LE, Aljenedil S, Rivière JB, Ruel I, Genest J.
    Eur J Prev Cardiol; 2019 Aug 21; 26(12):1262-1270. PubMed ID: 30755017
    [Abstract] [Full Text] [Related]

  • 18. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.
    Miname MH, Bittencourt MS, Moraes SR, Alves RIM, Silva PRS, Jannes CE, Pereira AC, Krieger JE, Nasir K, Santos RD.
    JACC Cardiovasc Imaging; 2019 Sep 21; 12(9):1797-1804. PubMed ID: 30448145
    [Abstract] [Full Text] [Related]

  • 19. Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.
    Rizos CV, Florentin M, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalidis E, Kolovou G, Garoufi A, Bilianou E, Koutagiar I, Agapakis D, Kiouri E, Antza C, Katsiki N, Zacharis E, Attilakos A, Sfikas G, Anagnostis P, Panagiotakos DB, Liberopoulos EN.
    Lipids Health Dis; 2020 May 28; 19(1):114. PubMed ID: 32466791
    [Abstract] [Full Text] [Related]

  • 20. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E, French FH Registry group.
    Atherosclerosis; 2018 Oct 28; 277():334-340. PubMed ID: 30270068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.